This mutation, present in nearly all cases of classic HCL, drives the constitutive activation of the MAPK/ERK pathway, promoting cell survival and proliferation while inhibiting apoptosis [5,12]. Detection of this mutation ruled out HCL-v, which lacks the BRAF V600E mutation, and helped distinguish the disease from morphologically similar conditions. This evidence concerns the gene BRAF and hairy cell leukemia.